News & Updates
Filter by Specialty:
PARG inhibition slows HCC progression, boosts efficacy of immune checkpoint therapy
In hepatocellular carcinoma (HCC), poly(ADP-ribose) glycohydrolase (PARG) may serve as an oncogene by modulating PARG/DDB1/c-Myc signaling and be used as a biomarker to identify HCC patients who may derive benefit from anti-PD-1 treatment, suggests a study.
PARG inhibition slows HCC progression, boosts efficacy of immune checkpoint therapy
05 Jul 2022
Surgery helps avoid castrate-resistant state in men with metastatic prostate cancer
In men with metastatic prostate cancer, prior radical prostatectomy (RP) appears to reduce the risk of developing a castrate-resistant state, as compared with radiation therapy (RT), according to a recent study. Previous RP also seems to improve overall survival (OS).
Surgery helps avoid castrate-resistant state in men with metastatic prostate cancer
05 Jul 2022
Stage II CRC: ctDNA guidance reduces adjuvant chemo use, does not increase recurrence
Using circulating tumour DNA (ctDNA) analysis to guide adjuvant treatment of stage II colorectal cancer (CRC) reduces adjuvant chemotherapy use without compromising recurrence-free survival (RFS) compared with standard management guided by clinicopathological criteria, results of a phase II randomized controlled trial have shown.
Stage II CRC: ctDNA guidance reduces adjuvant chemo use, does not increase recurrence
05 Jul 2022
Concurrent DOAC, tamoxifen use poses no elevated bleeding risk
In breast cancer patients receiving direct oral anticoagulants (DOACs), tamoxifen is safe to use and does not increase the risk of haemorrhage as compared with concurrent use of an aromatase inhibitor (AI), a study has found.
